Amgen’s Mvasi (bevacizumab) biosimilar has been granted a pan- European marketing authorisation by the European Commission, representing the first biosimilar of Genentech’s Avastin (bevacizumab) treatment for multiple forms of cancer approved in the European Union (EU), as well as the first European approval stemming from Amgen’s biosimilars development partnership with Allergan.
No launch date has been forecast by the development partners, although Genentech parent Roche noted last year that “basic, primary...
